GLYC vs. RLYB, ALRN, ELDN, BTAI, CKPT, MNOV, VHAQ, AFMD, LTRN, and LPTX
Should you be buying GlycoMimetics stock or one of its competitors? The main competitors of GlycoMimetics include Rallybio (RLYB), Aileron Therapeutics (ALRN), Eledon Pharmaceuticals (ELDN), BioXcel Therapeutics (BTAI), Checkpoint Therapeutics (CKPT), MediciNova (MNOV), Viveon Health Acquisition (VHAQ), Affimed (AFMD), Lantern Pharma (LTRN), and Leap Therapeutics (LPTX). These companies are all part of the "pharmaceutical preparations" industry.
Rallybio (NASDAQ:RLYB) and GlycoMimetics (NASDAQ:GLYC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation, community ranking and institutional ownership.
In the previous week, GlycoMimetics had 3 more articles in the media than Rallybio. MarketBeat recorded 5 mentions for GlycoMimetics and 2 mentions for Rallybio. GlycoMimetics' average media sentiment score of 0.93 beat Rallybio's score of 0.66 indicating that Rallybio is being referred to more favorably in the media.
GlycoMimetics received 282 more outperform votes than Rallybio when rated by MarketBeat users. However, 73.33% of users gave Rallybio an outperform vote while only 62.62% of users gave GlycoMimetics an outperform vote.
Rallybio has a beta of -1.63, meaning that its share price is 263% less volatile than the S&P 500. Comparatively, GlycoMimetics has a beta of 2.3, meaning that its share price is 130% more volatile than the S&P 500.
GlycoMimetics has higher revenue and earnings than Rallybio. Rallybio is trading at a lower price-to-earnings ratio than GlycoMimetics, indicating that it is currently the more affordable of the two stocks.
GlycoMimetics' return on equity of -66.59% beat Rallybio's return on equity.
Rallybio currently has a consensus price target of $12.20, indicating a potential upside of 630.54%. GlycoMimetics has a consensus price target of $10.00, indicating a potential upside of 3,590.04%. Given Rallybio's higher possible upside, analysts clearly believe GlycoMimetics is more favorable than Rallybio.
90.3% of Rallybio shares are owned by institutional investors. Comparatively, 75.2% of GlycoMimetics shares are owned by institutional investors. 7.4% of Rallybio shares are owned by company insiders. Comparatively, 8.7% of GlycoMimetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
GlycoMimetics beats Rallybio on 9 of the 16 factors compared between the two stocks.
Get GlycoMimetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GlycoMimetics Competitors List
Related Companies and Tools
